文献速递淋巴瘤

弥漫性大B细胞淋巴瘤的液体活检基因分型

Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
PubMed 文献 · Blood · 2017-01-17

本研究旨在利用血浆游离DNA(cfDNA)追踪弥漫性大B细胞淋巴瘤(DLBCL)的基线基因图谱及其治疗后的变化。对治疗前血浆cfDNA进行超深度靶向二代测序,以>90%灵敏度和约100%特异度正确发现了肿瘤活检中等位基因占比>20%的DLBCL相关突变,并可纵向监测R-CHOP化疗下的克隆演变和耐药克隆出现。

要点

  • 血浆cfDNA基因分型可准确检测DLBCL相关突变,灵敏度>90%、特异度约100%。
  • R-CHOP敏感患者cfDNA中DLBCL突变快速清除,耐药患者基线突变持续存在。
  • 耐药患者cfDNA中出现新突变,标记克隆演变中选择出的耐药克隆。

核心结论

  • cfDNA基因分型检测克隆性体细胞肿瘤突变的准确性可与诊断性活检基因分型相媲美,是实时、无创追踪克隆演变和耐药克隆出现的途径。

研究设计与样本

  • 对DLBCL患者治疗前血浆cfDNA进行超深度靶向二代测序,并与肿瘤活检结果比较。
  • 纵向分析R-CHOP化疗期间采集的血浆样本。

主要发现

  • 治疗前血浆cfDNA正确发现了肿瘤活检中等位基因占比>20%的DLBCL相关突变,灵敏度>90%、特异度约100%。
  • 血浆cfDNA基因分型可回收组织活检中检测不到的突变,可能因空间肿瘤异质性使这些突变局限于解剖上远离活检部位的克隆。
  • R-CHOP化疗下纵向分析显示,应答患者cfDNA中DLBCL突变快速清除;耐药患者基线DLBCL突变未从cfDNA中消失。
  • 耐药患者cfDNA中获得新突变,标记克隆演变中选择出的耐药克隆。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is increasingly impelling in diffuse large B-cell lymphoma (DLBCL). Cell-free DNA (cfDNA) is shed into the blood by tumor cells undergoing apoptosis and can be used as source of tumor DNA for the identification of DLBCL mutations, clonal evolution, and genetic mechanisms of resistance. In this study, we aimed at tracking the basal DLBCL genetic profile and its modification upon treatment using plasma cfDNA. Ultra-deep targeted next generation sequencing of pretreatment plasma cfDNA from DLBCL patients correctly discovered DLBCL-associated mutations that were represented in >20% of the alleles of the tumor biopsy with >90% sensitivity and ∼100% specificity. Plasma cfDNA genotyping also allowed for the recovery of mutations that were undetectable in the tissue biopsy, conceivably because, due to spatial tumor heterogeneity, they were restricted to clones that were anatomically distant from the biopsy site. Longitudinal analysis of plasma samples collected under rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) chemotherapy showed a rapid clearance of DLBCL mutations from cfDNA among responding patients. Conversely, among patients who were resistant to R-CHOP, basal DLBCL mutations did not disappear from cfDNA. In addition, among treatment-resistant patients, new mutations were acquired in cfDNA that marked resistant clones selected during the clonal evolution. These results demonstrate that cfDNA genotyping of DLBCL is as accurate as genotyping of the diagnostic biopsy to detect clonally represented somatic tumor mutations and is a real-time and noninvasive approach to tracking clonal evolution and the emergence of treatment-resistant clones.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017. PMID: 28096087. doi:10.1182/blood-2016-05-719641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。